Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.

 
      
    

查看其它語言版本

新聞

亞洲證券市場報告2015年11月26日- Regeneus Ltd (ASX:RGS)開始犬類癌症疫苗試驗

🕔11/26/2015 10:13:55 AM 11548

Regeneus (ASX:RGS),一家臨床階段再生醫藥公司,今天宣布開始其犬類癌症疫苗技術Kvax試驗,結合化學​​療法治療犬類淋巴瘤。

閱讀全文
###

236,031 公司背景瀏覽

  • 本頁瀏覽人次: (過去7日: 27) (過去30日: 170) (自發布以來: 22582) 

公司詳細

    總部
  • 2 Paddington Street
    Paddington NSW 2021
    Australia
  • 電話
  • +61-2-9499-8010 
  • 傳真
  • +61-2-9499-8020 
  • 主要部門
  • 醫療-製藥 
  • 支柱產業
  • 生物科技 
  • 主頁
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

更多新聞紀錄

  • 2024/04/08: Proposed issue of securities - RGS*
  • 2024/04/08: Ceasing to be a substantial holder - Kirman 2*
  • 2024/04/08: Ceasing to be a substantial holder - Lee*
  • 2024/04/08: Ceasing to be a substantial holder - Vesey*
  • 2024/04/08: Change of Company Name and ASX Code*
  • 2024/04/05: Cambium Bio Raises A$3.48 Million in Strategic Placement*
  • 2024/04/05: Final Director's Interest Notice - Leo Lee*
  • 2024/04/05: Director Resignation - Leo Lee*
  • 2024/04/05: Notice of initial substantial holder*
  • 2024/04/05: Initial Director's Interest Notice - Waller*
*refer to company website

Presentations

下載演示

財務報告

下載年報

社會化媒體